ERBB2 and glioblastoma: Moreover, in a phase I dose-escalation trial of progressive glioblastoma (GBM) patients without prior lymphodepletion, Ahmed et al. evaluated the feasibility and safety of CMV-Her2-CAR-T cells and reported a promising median overall survival (OS) of 11.1 months from the first T-cell infusion and 24.5 months from diagnosis [119].